|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn878805378 |
003 |
OCoLC |
005 |
20231120111559.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
140501s2014 cau ob 001 0 eng d |
040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d YDXCP
|d OCLCF
|d CHVBK
|d OCLCQ
|d YDX
|d U3W
|d D6H
|d OTZ
|d AU@
|d OCLCO
|d TKN
|d WYU
|d EBLCP
|d OCLCO
|d OCLCQ
|d OCLCA
|d OCLCQ
|d OCLCA
|d S2H
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCL
|d OCLCO
|
019 |
|
|
|a 959272263
|a 1057642582
|a 1058150854
|a 1086014445
|
020 |
|
|
|a 9780123820310
|q (electronic bk.)
|
020 |
|
|
|a 0123820316
|q (electronic bk.)
|
020 |
|
|
|z 9780123820303
|
020 |
|
|
|z 0123820308
|
035 |
|
|
|a (OCoLC)878805378
|z (OCoLC)959272263
|z (OCoLC)1057642582
|z (OCoLC)1058150854
|z (OCoLC)1086014445
|
050 |
|
4 |
|a RS403
|b .S55 2014eb
|
060 |
|
4 |
|a 2014 I-102
|
060 |
|
4 |
|a QV 744
|
082 |
0 |
4 |
|a 615.1/9
|2 23
|
100 |
1 |
|
|a Silverman, Richard B.,
|e author.
|
245 |
1 |
4 |
|a The organic chemistry of drug design and drug action.
|
250 |
|
|
|a Third edition /
|b Richard B. Silverman, Mark W. Holladay.
|
264 |
|
1 |
|a San Diego, CA :
|b Academic Press,
|c [2014]
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Introduction -- Lead discovery and lead modification -- Receptors -- Enzymes -- Enzyme inhibition and inactivation -- Dna-interactive agents -- Drug resistance and drug synergism -- Drug metabolism -- Prodrugs and drug delivery systems.
|
588 |
0 |
|
|a Print version record.
|
520 |
0 |
|
|a The Organic chemistry of drug design and drug action, Third edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage.
|
650 |
|
0 |
|a Pharmaceutical chemistry.
|
650 |
|
0 |
|a Bioorganic chemistry.
|
650 |
|
0 |
|a Molecular pharmacology.
|
650 |
|
0 |
|a Drugs
|x Design.
|
650 |
|
0 |
|a Chemistry, Organic.
|
650 |
|
0 |
|a Pharmacokinetics.
|
650 |
|
2 |
|a Chemistry, Pharmaceutical
|0 (DNLM)D002626
|
650 |
|
2 |
|a Chemistry, Organic
|0 (DNLM)D002625
|
650 |
|
2 |
|a Drug Design
|0 (DNLM)D015195
|
650 |
|
2 |
|a Pharmacokinetics
|0 (DNLM)D010599
|
650 |
|
6 |
|a Chimie pharmaceutique.
|0 (CaQQLa)201-0028674
|
650 |
|
6 |
|a Chimie bio-organique.
|0 (CaQQLa)201-0150662
|
650 |
|
6 |
|a Pharmacologie mol�eculaire.
|0 (CaQQLa)201-0165543
|
650 |
|
6 |
|a M�edicaments
|x Conception.
|0 (CaQQLa)201-0203461
|
650 |
|
6 |
|a Chimie organique.
|0 (CaQQLa)201-0004956
|
650 |
|
6 |
|a Pharmacocin�etique.
|0 (CaQQLa)201-0070307
|
650 |
|
7 |
|a organic chemistry.
|2 aat
|0 (CStmoGRI)aat300054541
|
650 |
|
7 |
|a Pharmacokinetics
|2 fast
|0 (OCoLC)fst01060250
|
650 |
|
7 |
|a Chemistry, Organic
|2 fast
|0 (OCoLC)fst00853501
|
650 |
|
7 |
|a Bioorganic chemistry
|2 fast
|0 (OCoLC)fst00832648
|
650 |
|
7 |
|a Drugs
|x Design
|2 fast
|0 (OCoLC)fst00898790
|
650 |
|
7 |
|a Molecular pharmacology
|2 fast
|0 (OCoLC)fst01024822
|
650 |
|
7 |
|a Pharmaceutical chemistry
|2 fast
|0 (OCoLC)fst01060115
|
700 |
1 |
|
|a Holladay, Mark W.,
|e author.
|
776 |
0 |
8 |
|i Print version:
|a Silverman, Richard B.
|t Organic chemistry of drug design and drug action.
|b Third edition
|z 9780123820303
|w (DLC) 2013043146
|w (OCoLC)861789148
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780123820303
|z Texto completo
|
856 |
4 |
1 |
|u https://sciencedirect.uam.elogim.com/science/book/9780123820303
|z Texto completo
|